Content area
Full Text
The Therapeutic Goods Administration (TGA) has provisionally approved the Moderna COVID-19 vaccine, SPIKEVAX, for use in individuals aged 6 years and older.
The decision follows the provisional approvals granted by the TGA to Moderna for the use of SPIKEVAX in individuals aged 12 years and older on 3 September 2021, and on 7 December 2021 the SPIKEVAX booster dose for use in adults 18 years and older.
As for other age groups, the use of this vaccine in children aged 6-11 years should be administered as 2 doses at least 28 days apart. The same vaccine preparation employed for older age groups will be used, however, a lower dose of 0.25 mL...